Jci_page_head_homepage_01 Jci_page_head_homepage_02
R. Gisli Jenkins, Xiao Su, George Su, Christopher J. Scotton, Eric Camerer, Geoffrey J. Laurent, George E. Davis, Rachel C. Chambers, Michael A. Matthay, Dean Sheppard
Published in Volume 116, Issue 6
J Clin Invest. 2006; 116(6):1606–1614 doi:10.1172/JCI27183
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4
PAR1 peptide–induced αv β6 -dependent TGF-β activity is PAR1 receptor specific.

(A) αvβ6-dependent TGF-β activity following stimulation of mouse embryonic fibroblast cells, stably transfected with human WT β6, with increasing doses of the PAR1-activating peptides TFLLRN and SFLLRN or the scrambled peptide control (FSLLRN), which has no known PAR1-activating effect. αvβ6-dependent TGF-β activity was calculated from coculture bioassays with TML cells, by comparison of the difference in luciferase activity in the absence and presence of αvβ6 blocking antibody with values obtained from a standard curve performed in coculture experiments with increasing concentrations of recombinant TGF-β. (B) After infection with a retroviral vector expressing WT human β6, αvβ6 expression in lung fibroblasts from Par1–/– mice that were either null (Par1–/–) or reconstituted with WT PAR1 (Par1+) was assessed by flow cytometry. (C) αvβ6-expressing Par1–/– and Par1+ fibroblasts were stimulated with increasing doses of SFLLRN, and αvβ6-dependent TGF-β activity was measured by coculture bioassay.